ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Saturday, November 6, 2021

11:15AM-11:30AM: Abstract Number: 0455

Abatacept Reverses Subclinical Arthritis in Patients with High-risk to Develop Rheumatoid Arthritis -results from the Randomized, Placebo-controlled ARIAA Study in RA-at Risk Patients

Plenary I (0453–0457)

11:15AM-11:30AM: Abstract Number: 0465

Cost-effectiveness of Treatment Strategies Involving Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear

Abstracts: Health Services Research (0462–0465)

11:15AM-11:30AM: Abstract Number: 0469

Imaging Characteristics in Patients with Spondyloarthritis Using a Novel Heel Enthesitis Magnetic Resonance Imaging Scoring (HEMRIS) System: Post-hoc Analysis of a Phase 3 Secukinumab Trial

Abstracts: Imaging of Rheumatic Diseases (0466–0469)

11:15AM-11:30AM: Abstract Number: 0461

Plasmablast-derived Autoantibodies from Individuals At-risk for RA That Target RA-relevant Antigens Are Polyreactive with Arthritogenic Bacteria

Abstracts: RA – Etiology & Pathogenesis (0458–0461)

11:15AM-11:30AM: Abstract Number: 0475

Quantitative Analysis of Gender and Racial Disparities in Randomized Controlled Trials of Fibromyalgia

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

11:15AM-11:30AM: Abstract Number: 0471

Therapeutic Efficacy of BT-104, an Oral LANCL2 Agonist, for the Treatment of Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models (0470–0473)

11:30AM-11:45AM: Abstract Number: 0472

An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species

Abstracts: SLE – Animal Models (0470–0473)

11:30AM-11:45AM: Abstract Number: 0476

Factors Associated with Pain Reduction and Improved Well-Being Among Fibromyalgia Patients Using Medical Cannabis

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

11:30AM-11:45AM: Abstract Number: 0456

Functional Connectivity, Enhanced Blood-Brain Barrier Leakage and Cognitive Impairment in Systemic Lupus Erythematosus

Plenary I (0453–0457)

11:45AM-12:00PM: Abstract Number: 0473

Disease-Associated Microglia Are Implicated in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models (0470–0473)

11:45AM-12:00PM: Abstract Number: 0457

Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination

Plenary I (0453–0457)

11:45AM-12:00PM: Abstract Number: 0477

TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial

Abstracts: Fibromyalgia & Other Clinical Pain Syndromes (0474–0477)

2:00PM-2:15PM: Abstract Number: 0488

Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial

Abstracts: Spondyloarthritis Including PsA – Treatment I: Emerging Therapies (0488–0491)

2:00PM-2:15PM: Abstract Number: 0478

Identification of Clinical Phenotypes of Hand Osteoarthritis Using Hierarchical Clustering Method

Abstracts: Osteoarthritis – Clinical (0478–0483)

2:00PM-2:15PM: Abstract Number: 0484

RheumMadness: Creating an Online Community of Inquiry

Abstracts: Professional Education (0484–0487)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].